『The GLP-1 Drug That Comes Next And More (with Dr Fatima Cody Stanford, Harvard Medical School)』のカバーアート

The GLP-1 Drug That Comes Next And More (with Dr Fatima Cody Stanford, Harvard Medical School)

The GLP-1 Drug That Comes Next And More (with Dr Fatima Cody Stanford, Harvard Medical School)

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
A billion people worldwide are living with obesity. The medications finally work. And fewer than one in ten of the people who could benefit will get them by 2030. In this episode I'm joined by Dr Fatima Cody Stanford, obesity medicine physician-scientist at Massachusetts General Hospital and Associate Professor at Harvard Medical School. One of the first fellowship-trained obesity medicine physicians in the world, she has published over 300 peer-reviewed papers, sat on the 2025 US Dietary Guidelines Advisory Committee, and contributed to the Lancet Commission that redefined clinical obesity. Many of you will know her from Oprah's weight-loss special. We talk about what's coming next: the triple agonist retatrutide, which produced average weight loss of over 28% in trial results presented in June, with two thirds of people on the top dose finishing no longer clinically obese. We also cover why almost nobody will be able to get it, the black market already selling it, why people with type 2 diabetes lose less weight on these drugs, and the body dysmorphia that doesn't disappear when the weight does. 🎙 Hosted by: Marc McKe 📍 Featuring: Dr Fatima Cody Stanford, Massachusetts General Hospital & Harvard Medical School Follow Dr Stanford: Instagram: @askdrfatima Website: askdrfatima.com 🔗 Connect with Marc 📲 TikTok: @my.journey.with.marc 📸 Instagram: @my.journey.with.marc 📺 YouTube: @myjourneywithmarc 🎧 Podcast IG: @this.is.my.journey.podcast 🎧 New episodes every Tuesday at 6am. Sources referenced in this episode: - World Health Organization, first global guideline on the use of GLP-1 medicines in treating obesity, published 1 December 2025. - TRIUMPH-1 figures from Eli Lilly's topline release, 21 May 2026, and Dr Ania Jastreboff's presentation at the 86th ADA Scientific Sessions, 6 June 2026. Presented at conference and not yet peer-reviewed. - TRANSCEND-T2D-1, The Lancet, June 2026. Lancet Commission on the definition and diagnosis of clinical obesity, January 2025.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません